AmCad BioMed Corporation (TPEX:4188)
Taiwan · Delayed Price · Currency is TWD 14.60
-0.10 (-0.68%)
Jan 22, 2026, 1:30 PM CST
AmCad BioMed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 43.51 | 53.11 | 65.26 | 61.63 | 85.79 | 63.94 | Upgrade | |
Revenue Growth (YoY) | -25.47% | -18.62% | 5.88% | -28.16% | 34.17% | -23.96% | Upgrade |
Cost of Revenue | 20.71 | 20.17 | 24.23 | 23.58 | 25.13 | 21.61 | Upgrade |
Gross Profit | 22.81 | 32.93 | 41.02 | 38.05 | 60.67 | 42.33 | Upgrade |
Selling, General & Admin | 50.83 | 53.82 | 50.89 | 48.39 | 46.59 | 49.08 | Upgrade |
Research & Development | 43.69 | 43.78 | 44.12 | 54 | 50.95 | 49.42 | Upgrade |
Operating Expenses | 94.52 | 97.6 | 95.01 | 102.34 | 97.44 | 98.6 | Upgrade |
Operating Income | -71.72 | -64.66 | -53.99 | -64.3 | -36.77 | -56.26 | Upgrade |
Interest Expense | -0.11 | -0.18 | -0.12 | -0.12 | -0.14 | -0.09 | Upgrade |
Interest & Investment Income | 7 | 6.18 | 4.71 | 4.72 | 3.73 | 4.85 | Upgrade |
Currency Exchange Gain (Loss) | -0.52 | 0.02 | 0.09 | 1.7 | 1.98 | -0.75 | Upgrade |
Other Non Operating Income (Expenses) | 8.13 | 5.93 | 6.32 | 3.66 | 4.38 | 9.81 | Upgrade |
EBT Excluding Unusual Items | -57.22 | -52.72 | -42.98 | -54.35 | -26.82 | -42.44 | Upgrade |
Gain (Loss) on Sale of Investments | 0.46 | 0.03 | 0 | 0.02 | 0 | 0.02 | Upgrade |
Gain (Loss) on Sale of Assets | -0.1 | -0.19 | -0.17 | -0.01 | -0.08 | -0.64 | Upgrade |
Other Unusual Items | 0.02 | - | 0 | - | - | 0.04 | Upgrade |
Pretax Income | -56.84 | -52.88 | -43.15 | -54.34 | -26.89 | -43.03 | Upgrade |
Earnings From Continuing Operations | -56.83 | -52.88 | -43.15 | -54.34 | -26.89 | -43.03 | Upgrade |
Minority Interest in Earnings | 8.39 | 2.3 | -2.17 | 0.86 | 1.35 | 7.58 | Upgrade |
Net Income | -48.44 | -50.58 | -45.31 | -53.49 | -25.54 | -35.44 | Upgrade |
Net Income to Common | -48.44 | -50.58 | -45.31 | -53.49 | -25.54 | -35.44 | Upgrade |
Shares Outstanding (Basic) | 63 | 58 | 53 | 53 | 53 | 53 | Upgrade |
Shares Outstanding (Diluted) | 63 | 58 | 53 | 53 | 53 | 53 | Upgrade |
Shares Change (YoY) | 14.80% | 8.42% | 0.01% | - | 0.09% | 0.36% | Upgrade |
EPS (Basic) | -0.76 | -0.88 | -0.85 | -1.01 | -0.48 | -0.67 | Upgrade |
EPS (Diluted) | -0.76 | -0.88 | -0.85 | -1.01 | -0.48 | -0.67 | Upgrade |
Free Cash Flow | -42.16 | -54.57 | -41.89 | -34.81 | -41.3 | -50.37 | Upgrade |
Free Cash Flow Per Share | -0.67 | -0.95 | -0.79 | -0.65 | -0.78 | -0.95 | Upgrade |
Gross Margin | 52.41% | 62.02% | 62.87% | 61.73% | 70.71% | 66.21% | Upgrade |
Operating Margin | -164.82% | -121.77% | -82.73% | -104.33% | -42.86% | -87.99% | Upgrade |
Profit Margin | -111.32% | -95.24% | -69.44% | -86.79% | -29.78% | -55.43% | Upgrade |
Free Cash Flow Margin | -96.88% | -102.76% | -64.20% | -56.48% | -48.14% | -78.77% | Upgrade |
EBITDA | -61.29 | -51.94 | -41.26 | -51.48 | -23.46 | -42.01 | Upgrade |
EBITDA Margin | -140.86% | -97.81% | -63.22% | -83.52% | -27.35% | -65.70% | Upgrade |
D&A For EBITDA | 10.43 | 12.72 | 12.73 | 12.82 | 13.31 | 14.26 | Upgrade |
EBIT | -71.72 | -64.66 | -53.99 | -64.3 | -36.77 | -56.26 | Upgrade |
EBIT Margin | -164.82% | -121.77% | -82.73% | -104.33% | -42.86% | -87.99% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.